AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10080605
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR 20 mg every 4 weeks
Trial: 10080605
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR 30 mg every 4 weeks
Trial: 7747843
Drug: Rectal sodium
RxNorm normalized name: Rectal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal sodium diclofenac 100 mg
Trial: 8467273
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment alone (Group C)
Trial: 31394282
Drug: Supervised progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised progressive resistance training (36 sessions, 1 hour each, 3 times weekly for 12 weeks)
Trial: 31394282
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no change in daily activity level)
Trial: 19156568
Drug: GHRH (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (100 microg as an intravenous bolus) with naloxone (2 mg bolus followed by 1.6 mg/h infusion)
Trial: 19156568
Drug: GHRH (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (100 microg as an intravenous bolus) without naloxone
Trial: 11074396
Drug: ss2-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ss2-agonist
Trial: 11074396
Drug: ss2-agonist and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ss2-agonist and ICS
Trial: 9512845
Drug: 0.54% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.54% hyperbaric lidocaine (48 mg)
Trial: 9512845
Drug: 0.3% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% hyperbaric lidocaine (72 mg)
Trial: 7836703
Drug: High prolactin
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High prolactin release (delta prolactin > 1000 mu u/ml, n = 11)
Trial: 7836703
Drug: Low prolactin
RxNorm normalized name: prolactin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low prolactin release (delta prolactin < 1000 mu u/ml, n = 8)
Trial: 2975199
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dapsone daily for 16 weeks
Trial: 2975199
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg 13‐cis retinoic acid daily for 16 weeks
Trial: 25204013
Drug: Magnesium lactate
RxNorm normalized name: Magnesium lactate
DrugBank: Magnesium lactate (DB14515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium lactate (360 mg elemental magnesium)
Trial: 22828734
Drug: Control (iso-energetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (iso-energetic and iso-proteinaceous supplement)
Trial: 20625131
Drug: Pyridoxine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (200 mg/d)
Trial: 12439645
Drug: Ephedrine and
RxNorm normalized name: Ephedrine and guaifenesin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine and caffeine (20/200 mg, three times daily) for 4 weeks
Trial: 9101609
Drug: Moderate renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate renal function deficit (CrCl 25 to 60 mL/min)
Trial: 9101609
Drug: Mild renal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild renal function deficit (CrCl >= 60 mL/min)
Trial: 2779901
Drug: Antibiotic regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic regimens in the trial
Trial: 1105628
Drug: Probenecid administration
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probenecid administration
Trial: 27562843
Drug: H1/H2-receptor blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1/H2-receptor blockers
Trial: 25465711
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (1 ml methylprednisolone acetate)
Trial: 25465711
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (1 ml methylprednisolone acetate + 15-day delayed 2 ml saline 0.9 %)
Trial: 25465711
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (1 ml methylprednisolone acetate + 15-day delayed 2 ml low molecular weight hyaluronic acid)
Trial: 17378196
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with point-injection
Trial: 11346005
Drug: Standard CSU‐13B/P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CSU‐13B/P anti‐G suit (STD)
Trial: 11346005
Drug: Advanced Technology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced Technology Anti‐G Suit (ATAGS)
Trial: 9741373
Drug: Nose mask
RxNorm normalized name: WITCH HAZEL 0.01 g in 100 g TOPICAL LIQUID [Charcoal Nose Mask Blackhead Remover]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nose mask CPAP therapy
Trial: 9741373
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask CPAP therapy
Trial: 9741373
Drug: Nose mask
RxNorm normalized name: WITCH HAZEL 0.01 g in 100 g TOPICAL LIQUID [Charcoal Nose Mask Blackhead Remover]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nose mask CPAP therapy for SAHS/U3P
Trial: 9741373
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask CPAP therapy for SAHS/U3P
Trial: 3127710
Drug: Electroencephalographic class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroencephalographic class 4 (abnormal before treatment and unchanged before withdrawal)
Trial: 1098526
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol
Trial: 17972380
Drug: Beta-blockers (betaB)
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (betaB)
Trial: 17972380
Drug: Angiotensin-renin system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-renin system blockers (ARSB)
Trial: 12494116
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors (ACEI)
Trial: 8562538
Drug: 0.5% aldose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% aldose reductase inhibitor (CT-112)
Trial: 327814
Drug: Fenoterol (prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (prophylactic administration)
Trial: 31431411
Drug: IIV4-HD (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4-HD (high-dose quadrivalent influenza vaccine)
Trial: 28532660
Drug: micro-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: micro-dose recombinant HCG
Trial: 11132533
Drug: IFN alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN alpha 6 MU tiw plus Ribavirin 14 mg/kg/day for 12 weeks
Trial: 9309491
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluoxetine and selegiline with physostigmine
Trial: 3565811
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (2.5 mg/kg in children; 4, 8, 12 mg/kg in dogs)
Trial: 3565811
Drug: Calcium gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium gluconate (7.5 mg/kg in children; 14, 28, 42 mg/kg in dogs)
Trial: 31017496
Drug: Intralesional verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional verapamil alone (2.5mg/ml)
Trial: 31017496
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pulsed dye laser (PDL) and intralesional verapamil (2.5mg/ml)
Trial: 30355464
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care and radiotherapy (daily schedule: 55 Gy in 20 fractions over 4 weeks; weekly schedule: 36 Gy in six fractions over 6 weeks)
Trial: 17850607
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus adjunctive CHX chip placement
Trial: 17850607
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus adjunctive systemic amoxicillin/metronidazole
Trial: 11902611
Drug: Anti-adhesive enamel
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-adhesive enamel coating applied to buccal surfaces of teeth in one quadrant
Trial: 7802306
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg immediately and droperidol 0.16 mg with each PCA dose (Group 1)
Trial: 7802306
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg immediately (Group 2)
Trial: 7802306
Drug: Droperidol 0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.16 mg with each PCA dose (Group 3)
Trial: 2148245
Drug: Large doses
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large doses of MPA (Depo-Provera)
Trial: 7053117
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% after interruption of local anaesthetic infusion
Trial: 28125821
Drug: MMC/5‐FU vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMC/5‐FU vs. no chemotherapy (necrosis present)
Trial: 28125821
Drug: MMC/5‐FU vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMC/5‐FU vs. no chemotherapy (necrosis absent)
Trial: 23685099
Drug: Automated intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated intermittent bolus (5 mL every 30 min with 0.1 mL/hr basal rate)
Trial: 23685099
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (10.1 mL/hr)
Trial: 21509750
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy plus standard care
Trial: 10446101
Drug: Bethanechol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol (5 mg subcutaneously)
Trial: 10446101
Drug: Atropine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.6 mg then 0.25 mg/hour intravenously)
Trial: 28849329
Drug: Lubiprostone 24
RxNorm normalized name: LUBIPROSTONE 24MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 mcg BID (CIC)
Trial: 28849329
Drug: Lubiprostone 24
RxNorm normalized name: LUBIPROSTONE 24MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 mcg BID (OIC)
Trial: 28849329
Drug: Lubiprostone 8
RxNorm normalized name: LUBIPROSTONE 8MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 8 mcg BID (IBS-C)
Trial: 15793171
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (PC) program
Trial: 11978650
Drug: Locally administered
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally administered insulin
Trial: 9579501
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with abrupt discontinuation (group 1A)
Trial: 9579501
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with abrupt discontinuation (group 2A)
Trial: 9579501
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with descending concentrations (group 1B)
Trial: 9579501
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 microg/ml) and fentanyl (1 ng/ml) with descending concentrations (group 2B)
Trial: 2482536
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b (Introna) 3 MU, 3 times weekly subcutaneously for 36 weeks
Trial: 320913
Drug: 5% solution
RxNorm normalized name: Introl 75% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% solution of metaproterenol, 10 whiffs (1.5 mg) q.i.d.
Trial: 320913
Drug: 0.5% isoproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% isoproterenol solution
Trial: 23705968
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity training (HIT) intervention - 3 weekly exercise sessions over 7 weeks, consisting of 4 to 6 repeats of maximal sprint running with 30 s recovery
Trial: 21726354
Drug: Hydrocortisone treatment
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone treatment for 3 days
Trial: 21726354
Drug: Hydrocortisone treatment
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone treatment for 7 days
Trial: 17065118
Drug: Sutter implants
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutter implants
Trial: 14652361
Drug: Betaine 1.5
RxNorm normalized name: COCAMIDOPROPYL BETAINE 1.5 mg in 100 g TOPICAL CREAM [Srripo Amino Acid Facial Cleanser]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine 1.5 g/d
Trial: 14652361
Drug: Betaine 3
RxNorm normalized name: betaine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine 3 g/d
Trial: 14652361
Drug: Betaine 6
RxNorm normalized name: betaine 648 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine 6 g/d
Trial: 11247402
Drug: Holter ECG
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Holter ECG monitoring in patients with glucose metabolism disturbances
Trial: 11247402
Drug: Holter ECG
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Holter ECG monitoring in patients without glucose metabolism disturbances
Trial: 30284674
Drug: Ileocolonic release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileocolonic release peppermint oil (IC-PO) 182 mg
Trial: 30284674
Drug: Small intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small intestinal release peppermint oil (SI-PO) 182 mg
Trial: 26679155
Drug: Monitoring cerebral
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring cerebral oxygenation by near‐infrared spectroscopy (NIRS) combined with an evidence‐based treatment guideline
Trial: 26679155
Drug: No NIRS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No NIRS data and treatment as usual
Trial: 22278623
Drug: Benidipine +
RxNorm normalized name: manidipine
DrugBank: Manidipine (DB09238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benidipine + β-blocker
Trial: 18983246
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment during pregnancy
Trial: 18983246
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment during pregnancy
Trial: 10340686
Drug: Typical antipsychotic
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical antipsychotic agents
Trial: 9219699
Drug: TNFR:Fc 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFR:Fc 16 mg/m²
Trial: 2890459
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg with food
Trial: 2890459
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg with Gelusil
Trial: 2890459
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg with activated charcoal
Trial: 2890459
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg with propantheline
Trial: 27464467
Drug: Active e-cigarette
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active e-cigarette smoking (smoked a pre-determined number of puffs within 30-min using a liquid with 11 ng/ml nicotine)
Trial: 23299877
Drug: Overall gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall gel use
Trial: 12660312
Drug: Ayahuasca (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (0.6 and 0.85 mg of DMT/kg of body weight)
Trial: 12660312
Drug: Ayahuasca (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (high dose)
Trial: 12660312
Drug: Ayahuasca (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (low and high doses)
Trial: 8862490
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist and menotropin therapy
Trial: 1640854
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (EPI) at 25 ng/kg/min for 5.5 hours after a basal overnight insulin infusion (12 mU/kg/h)
Trial: 8853469
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion (EPI)
Trial: 18706202
Drug: 3-week group
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week group (cisplatin 75 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1 and 8 of a 21-day cycle)
Trial: 18706202
Drug: 4-week group
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week group (cisplatin 75 mg/m² on day 1 plus gemcitabine 1000 mg/m² on days 1, 8 and 15 of a 28-day cycle)
Trial: 12946549
Drug: Cyclosporine Capsule
RxNorm normalized name: Cyclosporine Capsules
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine Capsule Satisfaction Survey
Trial: 10701814
Drug: Blood cadmium
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood cadmium concentration (B-Cd) and urinary cadmium excretion (U-Cd) measurements
Trial: 8443032
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN; 20 mg orally)
Trial: 27468086
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) including aspirin plus clopidogrel 75 mg/d or prasugrel 10 mg/d (5 mg/d for those <60 kg or age ≥75 years)
Trial: 24334689
Drug: CC‐JEV (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC‐JEV (17 μg per dose)
Trial: 24334689
Drug: CC‐JEV (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC‐JEV (4 μg per dose)
Trial: 24334689
Drug: CC‐JEV (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC‐JEV (8 μg per dose)
Trial: 24334689
Drug: MB‐JEV (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MB‐JEV (17 μg per dose)
Trial: 20536495
Drug: Gliclazide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (up to 320 mg/day)
Trial: 18692876
Drug: Celecoxib, 100
RxNorm normalized name: Celecoxib, 100 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib, 100 mg at 9 pm for 1 month
Trial: 16002805
Drug: 4.1 mg
RxNorm normalized name: menthol 4.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.1 mg lutein (n = 8)
Trial: 16002805
Drug: 20.5 mg
RxNorm normalized name: acetaminophen 320.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.5 mg lutein (n = 8)
Trial: 10369152
Drug: Psychoeducational medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational medication management training
Trial: 1781976
Drug: Cognition enhancers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognition enhancers (CEs) - piracetam, acetyl‐L‐carnitine, nimodipine (NIM)
Trial: 6783205
Drug: Tea consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea consumption (2 litres of tea daily, 4 bags of 2 g Assam/Ceylon tea per litre, steeped for 5 minutes)
Trial: 6783205
Drug: Water consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water consumption (2 litres of tap water daily)
Trial: 31575299
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy plus usual care
Trial: 28004200
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin infusion
Trial: 26108255
Drug: Oxycodone DETERx®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone DETERx® (intact)
Trial: 26108255
Drug: Oxycodone DETERx®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone DETERx® (crushed)
Trial: 26108255
Drug: IR oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR oxycodone (crushed)